Biotech

Executive Summary For decades, neuropsychiatry was a field characterized by high failure rates and incremental progress, making it a challenging...

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American: CYBN) (Cboe Canada: CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to...

- Dosing is underway in the Phase 3 CYB003 PARADIGM program which comprises two 12-week randomized, double-blind, placebo-controlled studies (APPROACH™...

Investor Insights Podcast #55 featuring Dr. Roderick Wong, Founder and CIO of RTW Investments, offers a deep dive into the...

In a development few would have predicted just a few years ago, the Trump administration has voiced support for the...

May marks Mental Health Awareness Month, a time when society reflects on the growing crisis of depression and anxiety affecting...

In a recent interview on NewsNation's On Balance, FDA Commissioner Dr. Marty Makary affirmed that advancing psychedelic therapies is now...

Cybin Announces Additional Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Phase 3 Program Evaluating CYB003 - Strategic Partnership...

Cybin Partners with Osmind to Accelerate Commercial Preparation for its Clinical-Stage Psychiatry Programs - Cybin will leverage Osmind's 800-clinic network,...

In the fast-evolving landscape of biotechnology, one company is making waves in the mental health treatment space with its innovative...